Company: GANX
Filing Date: 2025-07-15
Form Type: 424B5
Source: 0001104659-25-068103
Chunk: 20

Company: Gain Therapeutics, Inc.
Filing Date: 2025-07-15
Form: 424B5
Chunk 20
---
 market to develop. In addition, the Pre-Funded Warrants and Common Warrants are not listed, and we do not intend to apply for listing of the Pre-Funded Warrants or Common Warrants on any securities exchange or trading system. Without an active market, the liquidity of the Pre-Funded Warrants and the Common Warrants is limited, and investors may be unable to liquidate their investments in the Pre-Funded Warrants or the Common Warrants.

Neither of the Pre-Funded Warrant or the Common Warrants entitle the holder to any rights as common stockholders until the holder exercises the Pre-Funded Warrant or Common Warrant for shares of our common stock.

Until you acquire shares of our common stock upon exercise of your Pre-Funded Warrants or Common Warrants, neither of the Pre-Funded Warrants or the Common Warrants will provide you any rights as a common stockholder. Upon exercise of your Pre-Funded Warrants or Common Warrants, you will be entitled to exercise the rights of a common stockholder only as to matters for which the record date occurs on or after the exercise date.

The Common Warrants in this offering are speculative in nature.

The Common Warrants in this offering do not confer any rights of common stock ownership on their holders, such as voting rights or the right to receive dividends, but rather merely represent the right to acquire shares of common stock at a fixed price during a fixed period of time. Specifically, commencing on the date of issuance, holders of the Common Warrants may exercise their right to acquire common stock and pay an exercise price of $ per share of common stock. The Common Warrants will be exercisable beginning on the date of issuance and expire on the fifth anniversary of the date of issuance.

Moreover, following this offering, the market value of the Common Warrants, if any, is uncertain and there can be no assurance that the market value of the Common Warrants will equal or exceed their imputed offering price. There can also be no assurance that the market price of the common stock will ever equal or exceed the exercise price of the Common Warrants and, consequently, whether it will ever be profitable for holders of the Common Warrants to exercise the Common Warrants.

<div align='center'>S-13</div>

TABLE OF CONTENTS

### USE OF PROCEEDS
We estimate that the net proceeds from this offering will be approximately $ million, or approximately $ million if the underwriter exercises its option to purchase additional securities in full, after deduct